CATX Relative Valuation
CATX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CATX is overvalued; if below, it's undervalued.
Historical Valuation
Perspective Therapeutics Inc (CATX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -12.76. The fair price of Perspective Therapeutics Inc (CATX) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 2.39 USD , Perspective Therapeutics Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：2.39
Fair
Undervalued
-1.60
PE
1Y
3Y
5Y
Trailing
Forward
0.06
EV/EBITDA
Perspective Therapeutics Inc. (CATX) has a current EV/EBITDA of 0.06. The 5-year average EV/EBITDA is -5.17. The thresholds are as follows: Strongly Undervalued below -30.68, Undervalued between -30.68 and -17.93, Fairly Valued between 7.58 and -17.93, Overvalued between 7.58 and 20.34, and Strongly Overvalued above 20.34. The current Forward EV/EBITDA of 0.06 falls within the Historic Trend Line -Fairly Valued range.
0.05
EV/EBIT
Perspective Therapeutics Inc. (CATX) has a current EV/EBIT of 0.05. The 5-year average EV/EBIT is -38.82. The thresholds are as follows: Strongly Undervalued below -302.36, Undervalued between -302.36 and -170.59, Fairly Valued between 92.95 and -170.59, Overvalued between 92.95 and 224.72, and Strongly Overvalued above 224.72. The current Forward EV/EBIT of 0.05 falls within the Historic Trend Line -Fairly Valued range.
277.61
PS
Perspective Therapeutics Inc. (CATX) has a current PS of 277.61. The 5-year average PS is 224.80. The thresholds are as follows: Strongly Undervalued below -785.62, Undervalued between -785.62 and -280.41, Fairly Valued between 730.01 and -280.41, Overvalued between 730.01 and 1235.23, and Strongly Overvalued above 1235.23. The current Forward PS of 277.61 falls within the Historic Trend Line -Fairly Valued range.
-2.46
P/OCF
Perspective Therapeutics Inc. (CATX) has a current P/OCF of -2.46. The 5-year average P/OCF is -7.42. The thresholds are as follows: Strongly Undervalued below -42.01, Undervalued between -42.01 and -24.72, Fairly Valued between 9.87 and -24.72, Overvalued between 9.87 and 27.16, and Strongly Overvalued above 27.16. The current Forward P/OCF of -2.46 falls within the Historic Trend Line -Fairly Valued range.
-1.91
P/FCF
Perspective Therapeutics Inc. (CATX) has a current P/FCF of -1.91. The 5-year average P/FCF is 2.68. The thresholds are as follows: Strongly Undervalued below -21.75, Undervalued between -21.75 and -9.54, Fairly Valued between 14.89 and -9.54, Overvalued between 14.89 and 27.10, and Strongly Overvalued above 27.10. The current Forward P/FCF of -1.91 falls within the Historic Trend Line -Fairly Valued range.
Perspective Therapeutics Inc (CATX) has a current Price-to-Book (P/B) ratio of 0.73. Compared to its 3-year average P/B ratio of 1.57 , the current P/B ratio is approximately -53.20% higher. Relative to its 5-year average P/B ratio of 1.89, the current P/B ratio is about -61.28% higher. Perspective Therapeutics Inc (CATX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -21.68%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -16.47% , the current FCF yield is about -100.00% lower.
0.73
P/B
Median3y
1.57
Median5y
1.89
-64.96
FCF Yield
Median3y
-21.68
Median5y
-16.47
Competitors Valuation Multiple
The average P/S ratio for CATX's competitors is 10.76, providing a benchmark for relative valuation. Perspective Therapeutics Inc Corp (CATX) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of -43.36%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CATX decreased by 25.08% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -4.10K to -12.43K.
The secondary factor is the Revenue Growth, contributed -43.36%to the performance.
Overall, the performance of CATX in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Perspective Therapeutics Inc (CATX) currently overvalued or undervalued?
What is Perspective Therapeutics Inc (CATX) fair value?
How does CATX's valuation metrics compare to the industry average?
What is the current P/B ratio for Perspective Therapeutics Inc (CATX) as of Dec 05 2025?
What is the current FCF Yield for Perspective Therapeutics Inc (CATX) as of Dec 05 2025?
What is the current Forward P/E ratio for Perspective Therapeutics Inc (CATX) as of Dec 05 2025?